Fig. 4

Molecular profile of Pladienolide-B-treated PDAC cell lines. A Western-blot analysis of p/tAKT p/tJNK in MIAPaCa-2 cell lines after 24 h Pladienolide-B treatment. Ponceau-stained membranes served as loading control reference (n = 6). B mRNA levels in malignancy-implicated genes. Values represent the log₁₀ of expression compared to vehicle-treated (n = 4). C mRNA levels of BCL-XL and BCL-XS in HPDE E6E7 and MIAPaCa-2 cells treated 24 h with or without (vehicle, control) Pladienolide-B (n = 4). D mRNA expressions of KRAS and KRAS4a in HPDE E6E7 and MIAPaCa-2 cells treated 24 h with or without (vehicle, control) Pladienolide-B (n = 4). E Ratio of Δ133TP53/TP53 mRNA levels in HPDE E6E7 and MIAPaCa-2 cells treated 24 h with or without (vehicle, control) Pladienolide-B (n = 4). Gene expression was normalized to ACTB expression. Asterisks indicate significant differences (*p < 0.05; **p < 0.01; ***p < 0.001)